C4 Therapeutics (CCCC) announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics initiated with an Equal Weight at Stephens
- C4 Therapeutics announces first patient dosed in CFT8919 clinical trial
- C4 Therapeutics Advances in Protein Degradation Therapy
- C4 Therapeutics files $400M mixed securities shelf
- C4 Therapeutics files to sell 4.87M shares of common stock for holders